nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 in a Phase 2, Multicenter, Open-label Tumor-Agnostic Trial: PRECISION 1
24
Mar2024
nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study
March 24, 2024AadiSite Support
24
Mar2024
Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT
March 24, 2024AadiSite Support
23
Mar2024
Analysis of inactivating TSC1 and TSC2 alterations in a real-world patient population with advanced gynecological cancers in the Foundation Medicine genomic database
March 23, 2024AadiSite Support